

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/250468 A2

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 31/573* (2006.01)
A61K 31/395 (2006.01) *A61P 5/00* (2006.01)
A61K 31/426 (2006.01) *C07C 209/44* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(21) International Application Number:

PCT/IB2021/000403

(22) International Filing Date:

09 June 2021 (09.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2020/000575

10 June 2020 (10.06.2020) IB

(71) Applicants: **NEUROCRINE BIOSCIENCES, INC.**

[US/US]; 12780 El Camino Real, San Diego, California
92130 (US). **SANOFI** [FR/FR]; 54 Rue De La Boétie,
75008 Paris (FR).

(72) Inventors: **PALMER, Andrew**; c/o Neurocrine Bio-

sciences, Inc., 12780 El Camino Real, California, San
Diego, California 92130 (US). **STIRN, Scott**; c/o Neuro-
crine Biosciences, Inc., 12780 El Camino Real, San Diego,
California 92130 (US). **RADISSON, Joel**; c/o Sanofi,
Patent Department, 54 rue de la Boétie, 75008 Paris (FR).

(74) Agent: **BOYLE, Craig D.** et al.; Fish & Richardson P.C.,

P. O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-V-[(1S)-2-CYCLOPROPYL-L-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-V-PROP-2-YNYL-L,3-THIAZOL-2-AMINE

(57) Abstract: The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).

WO 2021/250468 A2